ReproNovo raises $65 million to boost reproductive health innovations

ReproNovo, a biopharmaceutical company specializing in reproductive medicine and women's health, has announced the successful closure of a $65 million Series A financing round. This fundraising was spearheaded by Jeito Capital, with co-leads AXA IM Alts and M Ventures, and gained additional support from Ysios Capital and ALSA Ventures. The capital will primarily fund the advancement of ReproNovo's pipeline, which includes two pivotal Phase 2 clinical-stage assets aimed at addressing male infertility and adenomyosis. The company, established in 2021, is at the forefront of tackling urgent unmet needs in reproductive health domains. With a talented leadership team and robust development strategy, ReproNovo's initiatives include the development of RPN-001 (leflutrozole), targeting male infertility due to low testosterone, and RPN-002 (nolasiban), an innovative solution for managing adenomyosis and enhancing ART efficacy. Positioned strategically with its headquarters in Lausanne, Switzerland, and development centers in Copenhagen and Barcelona, ReproNovo is poised to make a significant impact on global reproductive health.